July 22, 2014 — Simbionix USA announced the signing of a collaboration agreement with Pie Medical Imaging BV. The company manufactures and distributes the 3mensio software, a clinical application that enables the visualization and analysis of patient computed tomography (CT) scans in both 2-D and 3-D modes. The collaboration will enable the exporting of the 3mensio Vascular model into the Simbionix simulation environment to form a comprehensive planning solution that combines 3DR, data analysis and simulation on the same platform.
The solution will allow physicians and clinical specialists to rehearse a procedure in a complete virtual environment without the need for physical tools. This will take users of the 3mensio software to the next level of preparedness for endovascular procedures, as it will allow added simulation insights. Cases created by the software may also be imported to the Angio Mentor simulator for full procedure practice using fluoroscopy, guidewires, catheters and other equipment that is used in the cath lab.
Simbionix’s PROcedure Rehearsal Studio (PRS) steps up simulation by enabling physicians to rehearse a complete endovascular procedure on a virtual 3-D anatomical model based on a specific patient's CT data. The virtual model can be used for simulating, analyzing and evaluating pre-operative surgical treatment options prior to performing an actual case, which may increase a physician's confidence in the upcoming procedure. Simbionix recently received CE mark for its patient specific simulation.
In addition, Simbionix PRS has recently been granted a patent in China. The company now has patents for this technology in three key countries: the U.S., U.K. and China. These patents represent recognition for Simbionix's comprehensive line of products.
Gary Zamler, Simbionix CEO, said, "Growing interest from the image analysis market, which 3mensio is part of, demonstrates the need for more comprehensive planning solutions. The ability to evaluate surgical treatment options using simulation anytime, anywhere, is a major factor in achieving the goal to increase patient safety and improve procedure outcomes. The collaboration agreement, CE mark and additional patent are all examples of the company's key position as a market leader and innovator in the field of medical simulation."
For more information: www.simbionix.com
July 16, 2024 
